Masimo (MASI) reported $504.6 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 5.4%. EPS of $0.98 for the same period compares to $0.63 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $502.58 million, representing a surprise of +0.40%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.84.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Masimo (MASI) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this medical technology company would post earnings of $0.77 per share when it actually produced earnings of $0.86, delivering a surprise of 11.69%.Over the last four quarters, th ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Developed along ...

As of Oct. 10, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to ...

Masimo Corporation (MASI) is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) efforts. The optimism, led by a solid second-quarter 2024 performance and solid product portfolio, is expected to contribute further. However, concerns regarding overdependence on its Signal Extraction Technology ("SET") unit and macroeconomic issues persist. Over the past year, this Zacks Rank #1 (Strong Buy) company's shares have gained 18.4% compared with the industry's 7.1% growth. ...

The company seems to be effecting a smooth transition in its leadership. Medical tech company Masimo (MASI 6.01%) had some significant C-suite news to report on Wednesday, and investors clearly welcomed this. They collectively pushed the company's stock up by 6% across the day, which made the shares stand out as the S&P 500 index sagged marginally during that trading session. Interim CEO named Masimo announced that its CEO Joe Kiani informed the board of directors that he has stepped down from his post. He ...

Masimo (MASI) shares soared 8.7% in the last trading session to close at $121.42. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8.5% loss over the past four weeks. The sharp upsurge in Masimo's shares can be attributed to the surprising news regarding the company's newly elected Board of Directors. On Sept. 19, per a public statement issued from Politan, activist investor Quentin Koffey, and his Politan Capital Management group ...

Activist investor Politan Capital won the two board seats it was seeking at medical technology company Masimo, defeating founder and CEO Joe Kiani and another director, Chris Chavez, at the shareholder vote. Masimo shares rose more than 2% in extended trading. Politan nominees Darlene Solomon and Bill Jellison will join Politan investment chief Quentin Koffey and former Johnson & Johnson executive Michelle Brennan, who obtained board seats in a prior proxy fight last year. "We look forward to meeting with, ...

Masimo (MASI) recently announced that a U.S. court has found Politan Capital and its managing partner, Quentin Koffey, guilty of violating a sealing order by releasing information from ongoing court proceedings in a press release dated Sept. 12. This incident is likely to become a critical factor in the lead-up to Masimo's 2024 Annual Meeting on Sept. 19, where Politan aims to replace several board members, potentially leading to the ousting of the company's longstanding CEO and founder, Joe Kiani. The ruli ...

Masimo Corporation (MASI) , on Friday, announced a partnership with Google. The tie-up aims to develop a new reference platform for original equipment manufacturers (OEMs) building Wear OS by Google smartwatches. OEMs who adopt the new Masimo platform will continue to design and produce their new smartwatches' physical exteriors. However, the devices' interiors, including optimized hardware and software components, biosensors, and a companion Android smartphone app, will be provided by Masimo. This is expec ...